Tag Archives: tafamidis

Finally-A Pivotal Role for CNS Surrogates

Pfizer’s tafamidis program for Transthyretin Familial Amyloid Polyneuropathy (acquired via the buyout of FoldRx) has reached the FDA, and the CNS Advisory Committee charged with assessing tafamidis in the treatment of this rare disease has made an equally rare, and … Continue reading

Posted in Uncategorized | Tagged , , , | Leave a comment